Kinvan Pvt. Ltd. commenced production of clavulanic acid, a crucial compound, widely used to treat bacterial infections. This marks a significant step towards reducing India’s reliance on China for active pharmaceutical ingredients (APIs).
Kinvan has begun producing small batches and is set to ramp up to full-scale production, targeting an output of 300 metric tons by the end of 2024. The company plans to invest ₹447.17 crore in building a facility with the capacity to produce 300 metric tons of clavulanic acid annually.
Clavulanic acid is an essential starting material for manufacturing amoxyclav, a combination of two medicines, with augmentin being the most well-known brand. Currently, India is heavily reliant on imports from China for this material.
However, with the government’s production-linked incentive (PLI) scheme, domestic production of clavulanic acid and penicillin G is expected to increase by the year’s end.
As reported by economictimes.indiatimes.com, Kinvan is reportedly in advanced stages of preparation, and large-scale fermentation is anticipated to begin soon, a source confirmed, calling it a positive move for the industry.
